"In the United States, annual sales generated by the branded product and a generic competitor (with which Acrux’s generic will compete) exceeded USD$23 million and 47,000 packs based on sales reported by IQVIA1."
a $23m market with a branded product and a generic competitor - so ACR will be the third competitor in this absolutely "lucrative" market. well hopefully the marketing team is on the ball here to relieve the others of sale shares - but at what cost?, how much do you throw at marketing a product that competes in a market with annual sales of $23m?.
Add to My Watchlist
What is My Watchlist?
